Can engineered bacteria revolutionize cancer treatment? – Cancer Research Institute

Cancer Research Institute (CRI) shared a post on LinkedIn:

“Can engineered bacteria revolutionize cancer treatment?

A new article from authors including CRI’s Director of Scientific Affairs, Samik Upadhaya, CRI Lloyd J. Old STAR Dr. Tal Danino of Columbia University, and former Associate of the CRI Anna-Maria Kellen Clinical Accelerator and Venture Fund, Dr. Ana Rosa Sáez Ibáñez, just published in Nature Biotechnology explores the potential of bacteria-based cancer therapy.

Key Highlights:

30 years of preclinical, clinical, and commercial advancements in bacterial cancer treatments
Insights into how synthetic biology is shaping microbial immunotherapy
Future directions for customizable, tunable, and effective tumor-targeting bacterial medicines

This must-read review uncovers the latest trends in cancer-fighting bacteria and their potential to become an indispensable tool in oncology.

Discover.”

Authors: Edward R. Ballister, Alexander Michels, Rosa L. Vincent, Lior Kreindler, Sreyan Chowdhury, Samik Upadhaya, Ana Rosa Saez-Ibañez, Tao Tu, Juraj Gottweis, Tal Danino

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Insight

OncoDaily

Insight

Can engineered bacteria revolutionize cancer treatment? – Cancer Research Institute